Chitosan-modified hollow manganese dioxide nanoparticles loaded with resveratrol for the treatment of spinal cord injury

Drug Delivery, 2022 · DOI: https://doi.org/10.1080/10717544.2022.2104957 · Published: January 1, 2022

Spinal Cord Injury Pharmacology Biomedical

Simple Explanation

Spinal cord injury can be made worse by oxidative stress and inflammation. This study uses nanoparticles made of manganese dioxide and modified with chitosan to deliver resveratrol, a drug, to the injury site. The goal is to help the drug cross the blood-spinal cord barrier and reduce the damage. The nanoparticles, called CM, were loaded with resveratrol (Res) to create CMR. Experiments showed that CMR could reduce oxidative stress by lowering levels of harmful molecules and increasing levels of protective enzymes. Further tests showed that CMR also reduced inflammation and neuronal apoptosis, suggesting that CM is a good material for delivering drugs to treat spinal cord injuries.

Study Duration

7 days

Participants

C57BL/6J mice

Evidence Level

In vitro and In vivo experiments

Key Findings

1
Chitosan modification enables HM to cross the blood–spinal cord barrier (BSCB) and deliver Res to the injury site.
2
CMR significantly alleviated oxidative stress by reducing ROS and MDA levels and increasing SOD and GSH levels.
3
CMR reduced inflammation and neuronal apoptosis by modulating the expression of inflammatory cytokines and apoptosis-related proteins.

Research Summary

This study successfully synthesized chitosan-modified hollow manganese dioxide nanoparticles (CM) to deliver resveratrol (Res) for spinal cord injury (SCI) treatment. In vitro and in vivo experiments showed that CM effectively transported Res to the injury site, inhibiting oxidative stress, inflammation, and neuronal apoptosis, and promoting motor function recovery in SCI mice. CMR can provide a new therapeutic strategy for clinical SCI treatment research.

Practical Implications

Targeted Drug Delivery

CM can serve as a drug delivery vehicle for SCI treatment, potentially improving drug efficacy and reducing side effects.

Therapeutic Strategy

CMR offers a new therapeutic approach by simultaneously addressing oxidative stress, inflammation, and neuronal apoptosis in SCI.

Clinical Translation

The findings provide a basis for further clinical research to evaluate the potential of CMR in treating SCI patients.

Study Limitations

1
The raw data required to reproduce these findings cannot be shared at this time as the data also forms part of an ongoing study.
2
Further studies are needed to optimize the dosage and administration route of CMR for SCI treatment.
3
The long-term effects and potential toxicity of CMR need to be evaluated in more detail.

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury